Navigation Links
Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting

Therapeutics 26, Poster Board #8 Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m. Location: Exhibit Hall, Los Angeles Convention Center

About INNO-406

INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.

Contact

INNOVIVE Pharmaceuticals
Steve Kelly
President and CEO
212-716-1820
or
Porter Novelli Life Sciences
Rachel Lipsitz
Media & Investor Relations
619-849-5378


'"/>




Page: 1 2

Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
(Date:8/27/2015)... 2015  Now that Intuitive Surgical, Inc.® has announced ... robot, hospitals with robotic surgery programs need to think ... see where they stand with robotic surgery. Are they ... they adopted best practices for safety? Should they plan ... ECRI Institute, which has nearly 50 years, ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
Breaking Medicine Technology:Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... Incorporated (NASDAQ: GPRO ) announced today that the Company ... 28, 2011 at approximately 4:00 pm Eastern Time (ET). The announcement ... pm ET.   The conference call will be webcast ... Company,s web site at www.gen-probe.com . An archived version of ...
... July 14, 2011 Span-America Medical Systems, Inc. (NASDAQ: ... rebroadcast of its conference call on Friday, July 29, 2011, ... be released after the regular close of trading the preceding ... will be available online at www.spanamerica.com under investor ...
Cached Medicine Technology:Gen-Probe Announces Webcast of Second Quarter 2011 Earnings Conference Call 2
(Date:8/27/2015)... ... , ... Mesa Community College graduate, Andrew Sypher (Mesa), is one ... rigor, leadership and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, ... medallion and a $7,500 scholarship to assist in his goal of becoming a foreign ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... cost to treat a patient with hemophilia is $175,000. Hemophilia is an inherited, ... and improving treatment. The RMHBDA exists to help raise funds for patients suffering ...
(Date:8/27/2015)... ... 2015 , ... According to an article published August 13 by ... many conversations between hernia experts surrounding the search for the ideal hernia mesh. With ... experts have different ideas about which is the best mesh for their patients. What ...
(Date:8/27/2015)... Denver, CO (PRWEB) , ... August 27, 2015 , ... ... author examined the current policing situation in the city of New Orleans, highlighting a ... Force, the firm is run by a tech oriented entrepreneur who worked with the ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... , is one of just 20 adult-only medical centers in the United States ... with failing hearts and lungs. The Extracorporeal Life Support Organization (ELSO) , ...
Breaking Medicine News(10 mins):Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4
... family history data supports heredity,s role in shoulder tendon tearsROSEMONT, ... rotator cuff tears are at increased ... published in the May 2009 issue of The ... (JBJS). "This strongly suggests genetic predisposition as a possible cause ...
... crisis improved long-term outcomes, study found , , FRIDAY, May ... drug during a coronary emergency can save lives and ... , The one-year risk of death or major heart ... episodes of acute coronary syndrome who received the drugs, ...
... Mexico -- thought to be source of outbreak -- reports ... -- The number of confirmed swine flu cases in the ... but the infections continue to be mild. , In response ... for all Americans against the never-before-seen flu strain, but the ...
... Presented at American Heart Association ATVB Conference Shows Reduction ... in Treated PatientsWASHINGTON and SAN FRANCISCO, May 1 ... announced the results of a sub-study of patients in ... received serial 64 slice multidetector computed tomography (MDCT) scans ...
... a leading online consumer advocacy group, has announced the ... skin care and anti-aging websites, http://www.NewImageSpecialists.com ... cosmetic market, New Image Specialists, growing popularity has led ... network of more than 300 medical spas and laser ...
... 1 SCOLR Pharma, Inc. (NYSE Amex: DDD ... 31, 2009. The Company will host a live conference ... Time).Bruce S. Morra, SCOLR Pharma,s President and CEO, stated, "Our ... lead product candidates, ibuprofen and pseudoephedrine, and the support of ...
Cached Medicine News:Health News:Rotator Cuff Tears: Are They All in the Family? 2Health News:Rotator Cuff Tears: Are They All in the Family? 3Health News:Cholesterol Drugs May Help in Cardiac Emergency 2Health News:Swine Flu Infections Near 110 in U.S. 2Health News:Swine Flu Infections Near 110 in U.S. 3Health News:Swine Flu Infections Near 110 in U.S. 4Health News:Swine Flu Infections Near 110 in U.S. 5Health News:Swine Flu Infections Near 110 in U.S. 6Health News:Swine Flu Infections Near 110 in U.S. 7Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5Health News:SignatureForum Introduces NewImageSpecialists.com 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 3Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 4Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 6Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: